Basic information Safety Supplier Related

2(1H)-Quinoxalinone,3,4-dihydro-3,3-dimethyl-(9CI)

Basic information Safety Supplier Related

2(1H)-Quinoxalinone,3,4-dihydro-3,3-dimethyl-(9CI) Basic information

Product Name:
2(1H)-Quinoxalinone,3,4-dihydro-3,3-dimethyl-(9CI)
Synonyms:
  • 2(1H)-Quinoxalinone,3,4-dihydro-3,3-dimethyl-(9CI)
  • 2(1H)-quinoxalinone, 3,4-dihydro-3,3-dimethyl-
  • 3,3-dimethyl-1,4-dihydroquinoxalin-2-one
  • Quinoxalin-2(1H)-one, 3,4-dihydro-3,3-dimethyl-
  • 3,3-dimethyl-1,2,3,4-tetrahydroquinoxalin-2-one
CAS:
80636-30-2
MF:
C10H12N2O
MW:
176.22
Product Categories:
  • PIPERIDINE
Mol File:
80636-30-2.mol
More
Less

2(1H)-Quinoxalinone,3,4-dihydro-3,3-dimethyl-(9CI) Chemical Properties

Melting point:
135-136 °C
Boiling point:
349.0±31.0 °C(Predicted)
Density 
1.079±0.06 g/cm3(Predicted)
storage temp. 
Keep in dark place,Inert atmosphere,Room temperature
pka
13.32±0.40(Predicted)
Appearance
White to yellow Solid
More
Less

Safety Information

HazardClass 
IRRITANT
HS Code 
2933998090
More
Less

2(1H)-Quinoxalinone,3,4-dihydro-3,3-dimethyl-(9CI) Usage And Synthesis

Synthesis Reference(s)

Journal of Medicinal Chemistry, 37, p. 758, 1994 DOI: 10.1021/jm00032a008

Synthesis

95-54-5

57-15-8

80636-30-2

GENERAL PROCEDURE: A representative procedure for the synthesis of 3,3-dimethyl-3,4-dihydroquinoxalin-2(1H)-ones from o-phenylenediamine and trichloro-tert-butanol is as follows: under nitrogen protection, 50% aqueous sodium hydroxide (0.42 mL, 5 equiv.) was added slowly and dropwise to cooled-to-0 °C o-phenylenediamine 1a (200 mg, 1 equiv.), 4-(trichloromethyl)tetrahydro-2H-pyran -4-ol (812 mg, 2 eq.) and N-benzyl-N,N-diethylethanaminium chloride (42 mg, 0.1 eq.) in dichloromethane (0.1 M) in a stirred mixture with a controlled dropwise addition time of 10-20 seconds. The reaction mixture was stirred at 0 °C and then gradually warmed to room temperature and continued stirring for 18 hours. The reaction process was monitored by analytical HPLC-MS. Upon completion of the reaction, the mixture was diluted with water (10 mL) until all solids were dissolved and the layers were subsequently separated. The aqueous layer was extracted with dichloromethane (3 x 20 mL). The organic layers were combined, dried with magnesium sulfate, filtered and the solvent evaporated to give the crude product. The crude product was purified by silica gel column chromatography with an elution gradient of 0-50% ethyl acetate/heptane. The purified solid was filtered through a Brinell funnel and washed with methyl tert-butyl ether (2×10 mL) to give the final 10,2,3,40,5,6-hexahydro-30H-spiro[pyran-4,20-quinoxalin]-30-one (310 mg, 77%) as a pale yellow powder.

References

[1] Tetrahedron Letters, 2016, vol. 57, # 39, p. 4386 - 4388
[2] Synthesis, 1982, # 1, p. 71 - 74

2(1H)-Quinoxalinone,3,4-dihydro-3,3-dimethyl-(9CI)Supplier

Nanjing Norris-Pharm Technology Co., Ltd
Tel
18652989687
Email
sales@norris-pharm.com
Jiangsu Aikon Biopharmaceutical R&D co.,Ltd.
Tel
025-66113011 17798518460
Email
cfzhang@aikonchem.com
9ding chemical ( Shanghai) Limited
Tel
4009209199
Email
sales@9dingchem.com
EnliPharma Technology Co., Ltd
Tel
0551-66399836 18955197623
Email
sales@enlipharma.com
Aloespharm Co., Ltd.
Tel
021-20960837
Email
market@aloespharm.com